Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445793 · ClinicalTrials.gov registry record
: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
A clinical trial of Cystic Fibrosis (CF), sponsored by National Jewish Health.
- Completed
- Registry status
- 5
- Enrollment target
- 1
- Study location
NCT03445793 is a study of Cystic Fibrosis (CF) that has completed, run by National Jewish Health. The registered enrollment target is 5 participants, below the 141-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03445793, a study of Cystic Fibrosis (CF), has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single center study of clinical and laboratory outcomes in patients ≥ 12 who transition from use of Orkambi to tez/iva. Clinical and laboratory measurements will be measured at baseline, 1 month, 3 months, and 6 months after initiation of tez/iva. Change from baseline at 6 months pre-specified will be reported. The length of study participation will be approximately 6 months.
Conditions Studied
Study Locations (1)
Colorado
- National Jewish Heatlh - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2019-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03445793
The ClinicalTrials.gov registry entry for NCT03445793 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (96% lower). The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 0 interventions.
NCT03445793 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03445793 about?
NCT03445793 is a clinical study titled ": TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)". This study is a single center study of clinical and laboratory outcomes in patients ≥ 12 who transition from use of Orkambi to tez/iva. Clinical and laboratory measurements will be measured at baseline, 1 month, 3 months, and 6 months after initiation of tez/iva. Change from baseline at 6 months pre...
What is the current status of trial NCT03445793?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2018-03-01. Estimated completion is 2019-11-01.
What conditions does trial NCT03445793 study?
This clinical trial studies the following conditions: Cystic Fibrosis (CF).
Who is sponsoring clinical trial NCT03445793?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03445793 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis (CF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
RECRUITING · Phase 3
-
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
-
Study With Phage for CF Subjects With Pseudomonas Lung Infection
RECRUITING · Phase 2
-
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.